Literature DB >> 22264767

Classification systems to improve assessment of risk of bias.

Isabelle Boutron1, Philippe Ravaud.   

Abstract

Mesh:

Year:  2012        PMID: 22264767     DOI: 10.1016/j.jclinepi.2011.09.006

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


× No keyword cloud information.
  5 in total

1.  Keep calm and carry on testing: a substantive reanalysis and critique of 'what is the evidence for and validity of return-to-sport testing after anterior cruciate ligament reconstruction surgery? A systematic review and meta-analysis'.

Authors:  Jacob John Capin; Lynn Snyder-Mackler; May Arna Risberg; Hege Grindem
Journal:  Br J Sports Med       Date:  2019-07-09       Impact factor: 13.800

2.  In randomization we trust? There are overlooked problems in experimenting with people in behavioral intervention trials.

Authors:  Jim McCambridge; Kypros Kypri; Diana Elbourne
Journal:  J Clin Epidemiol       Date:  2013-12-04       Impact factor: 6.437

Review 3.  Diagnosis, prevention and treatment of common lower extremity muscle injuries in sport - grading the evidence: a statement paper commissioned by the Danish Society of Sports Physical Therapy (DSSF).

Authors:  Lasse Ishøi; Kasper Krommes; Rasmus Skov Husted; Carsten B Juhl; Kristian Thorborg
Journal:  Br J Sports Med       Date:  2020-01-14       Impact factor: 13.800

4.  Incorporation of assessments of risk of bias of primary studies in systematic reviews of randomised trials: a cross-sectional study.

Authors:  Sally Hopewell; Isabelle Boutron; Douglas G Altman; Philippe Ravaud
Journal:  BMJ Open       Date:  2013-08-23       Impact factor: 2.692

5.  Poor reliability between Cochrane reviewers and blinded external reviewers when applying the Cochrane risk of bias tool in physical therapy trials.

Authors:  Susan Armijo-Olivo; Maria Ospina; Bruno R da Costa; Matthias Egger; Humam Saltaji; Jorge Fuentes; Christine Ha; Greta G Cummings
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.